Recent 8-K filings for ORGO

• May 7, 2026, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01 ◈ Earnings Releases

  Organogenesis Q1 revenue $36.3M (-58% YoY); net loss $53.2M; FY guidance lowered

  Net revenue $36.3M, down 58% YoY from $86.7M; Advanced Wound Care down 63% to $29.5M.

• February 26, 2026, 6:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Organogenesis reports record Q4 2025 revenue $225M; FY2026 guidance implies 25-38% decline

  Q4 2025 net product revenue $225.1M (+78% YoY); Advanced Wound Care $217.2M (+83% YoY).

• November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Organogenesis posts record Q3 revenue of $150.5M, raises FY2025 guidance

  Net product revenue $150.5M (+31% YoY); Advanced Wound Care $141.5M (+31%), Surgical & Sports Med $9.0M (+25%).

• September 25, 2025, 7:59 PM ET other material materiality 0.80 negative item 7.01item 8.01item 9.01

  Organogenesis second Phase 3 ReNu knee OA trial misses primary endpoint; pre-BLA meeting planned

  Second Phase 3 (n=594) did not meet primary endpoint: WOMAC pain reduction difference -0.5 favoring ReNu (p=0.0393 vs target p=0.023).

• August 7, 2025, 7:59 PM ET earnings materiality 0.85 negative item 1.01item 2.02item 9.01

  Organogenesis Q2 revenue down 23% to $100.8M; amends credit agreement, waives covenant test

  Net product revenue $100.8M (down 23% YoY); Advanced Wound Care fell 25%, Surgical & Sports Med up 16%.

• June 24, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.02item 5.07

  Organogenesis stockholders approve Series A conversion issuance and director elections at 2025 annual meeting

  Stockholders approved issuance of >20% of Class A common stock upon conversion of Series A Preferred at less than Nasdaq minimum price.

• May 8, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Organogenesis Q1 revenue down 21% to $86.7M; net loss widens to $18.8M; FY guidance reaffirmed

  Net revenue $86.7M, down 21% YoY; Advanced Wound Care fell 23% to $79.9M; Surgical & Sports Medicine up 11% to $6.8M.

• February 27, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Organogenesis Q4 revenue up 27% to $126.7M; net income $7.7M vs loss year ago; guides FY25 rev $480-535M

  Q4 net revenue $126.7M (+27%); Advanced Wound Care $118.6M (+27%), Surgical/Sports $8.1M (+24%).

• November 13, 2024, 6:59 PM ET other material materiality 0.80 positive item 1.01item 5.03item 2.04item 3.02item 3.03item 5.02item 8.01item 9.01 ◈ executive_change

  Organogenesis raises $130M convertible preferred, repurchases 7.4M shares, appoints Avista director

  Sold 130,000 shares of Series A Convertible Preferred Stock at $1,000/share for gross proceeds of $130M.

• November 12, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Organogenesis Q3 revenue up 6% to $115.2M, net income $12.3M vs $3.2M; updates FY guidance

  Net revenue $115.2M (+6% YoY); Advanced Wound Care $108.0M (+7%).

• August 8, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Organogenesis Q2 revenue up 11% but net loss $17M on $22.8M impairment and write-downs

  Net revenue $130.2M (+11% YoY); Advanced Wound Care $123.2M (+12%), Surgical & Sports Med $7.0M (-3%).

• May 9, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Organogenesis beats Q1 revenue guidance with $110.0M; net loss narrows to $2.1M

  Net revenue $110.0M, up 2% YoY, exceeding high-end of FY2024 guidance.

• February 29, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Organogenesis Q4 revenue $99.7M (-14% YoY); net loss $0.6M; FY2024 guides $445M-$470M

  Net revenue Q4 $99.7M (-14% YoY): Advanced Wound Care $93.2M (-14%), Surgical & Sports Medicine $6.5M (-3%).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

7 positive 7 negative 6 neutral

source · ORGO on sec.gov